Vistagen Therapeutics, Inc. — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Vistagen established an unfunded Executive Severance Plan (effective October 7, 2026) providing cash severance, COBRA benefits, and equity acceleration to eligible executives upon qualifying terminations. Tier structure ranges from CEO (individual agreement terms) to VP level (4 months base pay, 4 months bonus, 4 months COBRA). Change-in-Control terminations trigger enhanced benefits including full equity acceleration and bonus severance; non-CIC terminations receive base pay and COBRA only. Plan amends and restates prior August 2026 version.
Why this rating
Severance plan adoption is routine corporate governance. At $137.7M market cap, typical executive severance obligations (likely <$5M–10M aggregate across all tiers) represent modest liability. No change in operations, financials, or strategy. Standard protective measure.
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.